JP3713722B2 - Guayphenesin combination formulation - Google Patents
Guayphenesin combination formulation Download PDFInfo
- Publication number
- JP3713722B2 JP3713722B2 JP06634794A JP6634794A JP3713722B2 JP 3713722 B2 JP3713722 B2 JP 3713722B2 JP 06634794 A JP06634794 A JP 06634794A JP 6634794 A JP6634794 A JP 6634794A JP 3713722 B2 JP3713722 B2 JP 3713722B2
- Authority
- JP
- Japan
- Prior art keywords
- guaifenesin
- guayphenesin
- weight
- combination formulation
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Description
【0001】
【産業上の利用分野】
本発明はグアイフェネシンを配合した製剤に関し、さらに詳しくはグアイフェネシン配合時の安定性が改善された経口固型製剤組成物に関する。
【0002】
【従来の技術】
グアイフェネシンは化学名を3−(2−メトキシフェノキシ)−1,2−プロパンジオールと称し、去痰薬として効果が広く知られている薬物である。
【0003】
また、塩酸メトキシフェナミン、臭化水素酸デキストロメトルファンは鎮咳薬として、マレイン酸カルビノキサミンは抗ヒスタミン薬として、無水カフェインは中枢興奮薬として、さらにビスイブチアミンはビタミンB1誘導体として、それぞれ広く知られている。
【0004】
【発明が解決しようとする課題】
グアイフェネシンは、経口用の固型製剤を調整する際に、塩酸メトキシフェナミン、無水カフェイン、マレイン酸カルビノキサミン、ビスイブチアミン、又は臭化水素酸デキストロメトルファン等の物質と配合すると湿潤、変色等の製剤上の安定性が確保できなかった。
【0005】
また、湿式造粒後の乾燥工程が高温で処理できないことから長時間必要であるばかりか、結果として十分な乾燥ができなかった。
【0006】
さらに、錠剤を製する場合には打錠時に杵や臼内壁に付着が生じ、スティッキング等の打錠障害を起こしていた。
【0007】
【課題を解決するための手段】
本発明者らは、上記問題点に鑑み、鋭意検討を重ね、グアイフェネシンを有効成分として含有する経口用固形製剤において、グアイフェネシンを別に造粒し、他の薬物との接触を防止することで上記問題点を解決できることを見いだし、本発明を完成するに至った。
【0008】
すなわち本発明は、
(a)グアイフェネシン:及び
(b)塩酸メトキシフェナミン、無水カフェイン、マレイン酸カルビノキサミン、ビスイブチアミン、又は臭化水素酸デキストロメトルファンから選ばれる1種又は2種以上の物質:
を有効成分とし、これらを別々に造粒した経口固型製剤組成物である。
【0009】
本発明の組成物は、グアイフェネシンを含む(A)組成物と、塩酸メトキシフェナミン、無水カフェイン、マレイン酸カルビノキサミン、ビスイブチアミン、又は臭化水素酸デキストロメトルファンから選ばれる1種又は2種以上の物質を含む(B)組成物とからなり、これらをそれぞれ第12改正日本薬局方製剤総則に従って顆粒剤または散剤とする。各々の顆粒剤または散剤を混合し目的の顆粒剤または散剤を得、さらにこれを同総則に従って錠剤とすることで目的の錠剤を得ることができる。
【0010】
(A)には、グアイフェネシンの他に、澱粉、低置換度ヒドロキシプロピルセルロース、結晶セルロース、メタケイ酸アルミン酸マグネシウム、軽質無水ケイ酸、ヒドロキシプロピルセルロース、ヒドロキシプロピルメチルセルロース等の賦形剤、崩壊剤、結合剤、リボフラビン等の薬物を添加、配合し得る。(B)には、塩酸メトキシフェナミン、無水カフェイン、マレイン酸カルビノキサミン、ビスイブチアミン、臭化水素酸デキストロメトルファンの他に、上記以外の薬物、(A)と同様の賦形剤、崩壊剤、結合剤等を添加、配合することができる。また、より良好な製剤を得るために、(C)としてステアリン酸マグネシウム等の滑沢剤や、(A)と同様の賦形剤等を添加することも可能である。
【0011】
(A)成分全体におけるグアイフェネシンは、5〜50重量%が好ましく、特に10〜30重量%が好ましい。また、グアイフェネシン1重量部に対する(b)の物質のそれぞれの配合量は、塩酸メトキシフェナミン30〜150%重量部、無水カフェイン30〜150%重量部、マレイン酸カルビノキサミン1〜10%重量部、ビスイブチアミン4〜30%重量部、臭化水素酸デキストロメトルファン7〜50%重量部が好ましい。
【0012】
【発明の効果】
本発明により、グアイフェネシンを配合した経口固型製剤において、安定性が確保できたことにより製剤の湿潤、変色が起こらず、また、造粒時の乾燥も十分に行うことが可能となった。さらに打錠の際の杵、臼内壁への付着も無く、良好に製錠できるようになった。
【0013】
【実施例】
以下、実施例及び試験例を挙げて本発明を具体的に説明する。
【0014】
上記処方(A)585g、(B)2547gをそれぞれ第12改正日本薬局方製剤総則7に従い湿式造粒法により顆粒を調整し、これらに(C)18gを混合して同総則15に従い目的錠剤を9000錠得た。
【0015】
上記処方(A)350g、(B)850gをそれぞれ第12改正日本薬局方製剤総則13に従い散剤とし、これらを混合して目的散剤を1000包得た。
【0016】
上記処方(A)350g、(B)850gをそれぞれ第12改正日本薬局方製剤総則13に従い散剤とし、これらを混合して目的散剤を1000包得た。
【0017】
上記処方(A)1260g、(B)1734gをそれぞれ第12改正日本薬局方製剤総則13に従い散剤とし、これらに(C)6gを篩過して混合することで目的散剤を3000包得た。
【0018】
上記処方(A)1050g、(B)3450gをそれぞれ第12改正日本薬局方製剤総則13に従い散剤とし、これらを混合して目的散剤を3000包得た。
【0019】
試験例1
(検体)
実施例1で得られた顆粒を検体1とし、実施例1の処方(A)(B)の成分をすべて造粒前に混合して得られた顆粒を対照検体1とした。
(試験法)
検体1、対照検体1をそれぞれクリーンプレスコレクト19(菊水製作所製)を用いて打錠した。
(結果)
対照検体1を打錠した場合には、杵、臼内壁への顆粒の付着が起こったが、検体1では、顆粒の付着は全く起こらなかった。
【0020】
試験例2
(検体)
実施例1〜5における造粒前の粉末をそれぞれ検体1A,1B〜5A,5Bとし、またこれらの実施例の処方(A)(B)の成分をすべて混合して得られた粉末をそれぞれ対照検体1C〜5Cとした。
(試験法)
検体1A,1B〜5A,5B、対照検体1C〜5Cを湿式造粒した後、フローコーターミニ(フロイント産業製)で乾燥を行った。
(結果)
対照検体に比して検体の乾燥は高温で処理できるため、短時間で行うことが可能であり、十分な乾燥ができた。
【0021】
試験例3
(検体)
実施例1で得られた錠剤を検体6とし、また(A)成分におけるグアイフェネシン濃度を23、26、30重量%となるように調製した以外は実施例1と同様にして得られた錠剤をそれぞれ検体7、8、9とした。さらに対照検体として実施例1の処方(A)(B)の成分をすべて造粒前に混合して得られた錠剤を対照検体6とした。
(試験法)
各検体を65℃、50℃、40℃で保存して、1日後(1D)、1週間後(1W)、2週間後(2W)、1ヶ月後(1M)の錠剤の安定性の試験を行った。安定性は、外観の変色の度合を、以下に示す5段階で評価した。
- :変化無し
+1:僅かに変化を認める
+2:明かな変化を認める
+3:著しい変化を認める
+4:非常に著しい変化を認める
(結果)
試験結果を表1に示す。
【0022】
【表1】
[0001]
[Industrial application fields]
The present invention relates to a preparation containing guaifenesin, and more particularly to an oral solid preparation composition having improved stability when guaifenesin is added.
[0002]
[Prior art]
Guaifenesin is a drug whose chemical name is 3- (2-methoxyphenoxy) -1,2-propanediol and is widely known as an expectorant.
[0003]
In addition, methoxyphenamine hydrochloride and dextromethorphan hydrobromide are widely used as antitussives, carbinoxamine maleate as an antihistamine, anhydrous caffeine as a central stimulant, bibisbutiamine as a vitamin B 1 derivative. Are known.
[0004]
[Problems to be solved by the invention]
Guaifenesin can be used in preparation of oral solid preparations when mixed with substances such as methoxyphenamine hydrochloride, anhydrous caffeine, carbinoxamine maleate, bisbutiamine maleate, or dextromethorphan hydrobromide. It was not possible to ensure the stability of the preparation.
[0005]
Moreover, since the drying process after wet granulation cannot be processed at high temperature, it is not only necessary for a long time, but also as a result, sufficient drying could not be performed.
[0006]
Further, when tablets are produced, sticking occurs on the inner wall of the crease or the die during tableting, which causes tableting troubles such as sticking.
[0007]
[Means for Solving the Problems]
In view of the above-mentioned problems, the present inventors have conducted extensive studies and in the oral solid preparation containing guaifenesin as an active ingredient, the above-mentioned problem can be achieved by granulating guaifenesin separately and preventing contact with other drugs. The inventors have found that the problem can be solved and have completed the present invention.
[0008]
That is, the present invention
(A) guaifenesin: and (b) one or more substances selected from methoxyphenamine hydrochloride, caffeine anhydride, carbinoxamine maleate, bisbutiamine, or dextromethorphan hydrobromide:
Is an oral solid pharmaceutical composition in which these are granulated separately.
[0009]
The composition of the present invention comprises (A) a composition containing guaifenesin and one or two selected from methoxyphenamine hydrochloride, caffeine anhydride, carbinoxamine maleate, bisbutiamine, or dextromethorphan hydrobromide It consists of (B) composition containing the above substances, and these are each made into granules or powders in accordance with the 12th revised Japanese Pharmacopoeia General Rules for Preparations. Each granule or powder is mixed to obtain the desired granule or powder, and the desired tablet can be obtained by making this into a tablet according to the same general rules.
[0010]
In (A), in addition to guaifenesin, starch, low-substituted hydroxypropylcellulose, crystalline cellulose, magnesium aluminate metasilicate, light anhydrous silicic acid, hydroxypropylcellulose, hydroxypropylmethylcellulose and other excipients, disintegrants, Drugs such as a binder and riboflavin can be added and blended. (B) includes methoxyphenamine hydrochloride, anhydrous caffeine, carbinoxamine maleate, bisbutiamine, dextromethorphan hydrobromide, other drugs, excipients similar to (A), disintegration Agents, binders, etc. can be added and blended. Moreover, in order to obtain a better formulation, it is possible to add a lubricant such as magnesium stearate as (C) or an excipient similar to (A).
[0011]
(A) 5 to 50 weight% is preferable and, as for the guaifenesin in the whole component, 10 to 30 weight% is especially preferable. In addition, the compounding amount of the substance (b) with respect to 1 part by weight of guaifenesin is 30 to 150% by weight of methoxyphenamine hydrochloride, 30 to 150% by weight of anhydrous caffeine, 1 to 10% by weight of carbinoxamine maleate, Bisbuthiamine is preferably 4 to 30% by weight, and dextromethorphan hydrobromide 7 to 50% by weight.
[0012]
【The invention's effect】
According to the present invention, in an oral solid preparation containing guaifenesin, stability can be secured, so that the preparation does not wet or discolor, and can be sufficiently dried during granulation. In addition, there was no sticking to the inner wall of the mortar at the time of tableting, and it became possible to tablet well.
[0013]
【Example】
Hereinafter, the present invention will be specifically described with reference to examples and test examples.
[0014]
The above formulations (A) 585g and (B) 2547g were prepared by wet granulation according to the 12th revised Japanese Pharmacopoeia General Rules 7, respectively, and (C) 18g was mixed with them and the target tablets were prepared according to the same General Rules 15. 9000 tablets were obtained.
[0015]
350 g of the above-mentioned prescription (A) and 850 g of (B) were each used as powder according to the twelfth revised Japanese Pharmacopoeia General Rules for Preparation 13, and these were mixed to obtain 1000 target powders.
[0016]
350 g of the above-mentioned prescription (A) and 850 g of (B) were each used as powder according to the twelfth revised Japanese Pharmacopoeia General Rules for Preparation 13, and these were mixed to obtain 1000 target powders.
[0017]
The above-mentioned prescription (A) 1260g and (B) 1734g were each made into a powder according to the twelfth revised Japanese Pharmacopoeia General Formulation 13, and (C) 6g was sieved and mixed to obtain 3000 target powders.
[0018]
1050 g of the above-mentioned prescription (A) and 3450 g of (B) were each made into powder according to the twelfth revised Japanese Pharmacopoeia General Rules for Preparation 13, and these were mixed to obtain 3000 target powders.
[0019]
Test example 1
(Sample)
The granule obtained in Example 1 was designated as Sample 1, and the granule obtained by mixing all the ingredients of the formulation (A) and (B) of Example 1 before granulation was designated as Control Sample 1.
(Test method)
Specimen 1 and control specimen 1 were tableted using clean press collect 19 (manufactured by Kikusui Seisakusho).
(result)
When the control specimen 1 was tableted, adhesion of granules to the inner wall of the wrinkle and mortar occurred, but in specimen 1, no adhesion of granules occurred.
[0020]
Test example 2
(Sample)
The powders before granulation in Examples 1 to 5 were designated as Samples 1A, 1B to 5A and 5B, respectively, and the powders obtained by mixing all the ingredients of the formulations (A) and (B) of these Examples were respectively controlled. Samples 1C to 5C were used.
(Test method)
Samples 1A, 1B to 5A, 5B and control samples 1C to 5C were wet granulated and then dried with a flow coater mini (manufactured by Freund Corporation).
(result)
Compared with the control sample, the sample could be dried at a high temperature, so that it could be performed in a short time and was sufficiently dried.
[0021]
Test example 3
(Sample)
The tablets obtained in Example 1 were designated as Sample 6, and the tablets obtained in the same manner as in Example 1 except that the concentrations of guaifenesin in component (A) were 23, 26, and 30% by weight, respectively. Samples 7, 8, and 9 were used. Further, as a control sample, a tablet obtained by mixing all the components of the formulations (A) and (B) of Example 1 before granulation was used as a control sample 6.
(Test method)
Each specimen was stored at 65 ° C, 50 ° C, and 40 ° C and tested for tablet stability after 1 day (1D), 1 week (1W), 2 weeks (2W), and 1 month (1M). went. The stability was evaluated by the following five grades for the degree of discoloration of the appearance.
-: No change
+1: Slight change
+2: Recognize obvious changes
+3: Remarkable change
+4: A very significant change is recognized (result)
The test results are shown in Table 1.
[0022]
[Table 1]
Claims (1)
(b)塩酸メトキシフェナミン、無水カフェイン、マレイン酸カルビノキサミン、ビスイブチアミン、又は臭化水素酸デキストロメトルファンから選ばれる1種又は2種以上の物質:
を有効成分とし、これらを別々に造粒した経口固型製剤用組成物。(A) guaifenesin: and (b) one or more substances selected from methoxyphenamine hydrochloride, caffeine anhydride, carbinoxamine maleate, bisbutiamine, or dextromethorphan hydrobromide:
A composition for oral solid preparations, which is an active ingredient and granulated separately.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP06634794A JP3713722B2 (en) | 1994-04-05 | 1994-04-05 | Guayphenesin combination formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP06634794A JP3713722B2 (en) | 1994-04-05 | 1994-04-05 | Guayphenesin combination formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07277962A JPH07277962A (en) | 1995-10-24 |
JP3713722B2 true JP3713722B2 (en) | 2005-11-09 |
Family
ID=13313243
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP06634794A Expired - Lifetime JP3713722B2 (en) | 1994-04-05 | 1994-04-05 | Guayphenesin combination formulation |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP3713722B2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4828707B2 (en) * | 2000-02-28 | 2011-11-30 | 武田薬品工業株式会社 | Solid compression formulation |
JP4573542B2 (en) * | 2004-03-01 | 2010-11-04 | 塩野義製薬株式会社 | Vitamin B1 derivative composition |
JP5625360B2 (en) * | 2009-01-20 | 2014-11-19 | 大正製薬株式会社 | Method for stabilizing lysozyme hydrochloride |
JP6724537B2 (en) * | 2015-05-26 | 2020-07-15 | 大正製薬株式会社 | Solid formulation |
US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
-
1994
- 1994-04-05 JP JP06634794A patent/JP3713722B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPH07277962A (en) | 1995-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1818057B1 (en) | Stable pharmaceutical formulations of montelukast sodium | |
KR100554816B1 (en) | Pharmaceutical dosage form of amorphous nelfinavir mesylate | |
JP4610834B2 (en) | Oral solid preparation | |
EP0189114B1 (en) | Quinoline carboxylic acid tablet and formulation | |
JPS63301820A (en) | Pharmacological tablet, pharmacological granules and manufacture | |
JP6404886B2 (en) | Method for stabilizing pharmaceutical compositions containing irbesartan and amlodipine or a salt thereof | |
US20090324718A1 (en) | Imatinib compositions | |
JP2009524658A (en) | Levetiracetam preparation and method for producing the same | |
JP2002326927A (en) | Quick-releasing tablet containing metformin hydrochloride | |
JP2000119175A (en) | Intraoral rapid disintegrative solid preparation | |
JP2012509320A (en) | Wet granulation of tenofovir, emtricitabine and efavirenz | |
WO2011074660A1 (en) | Elution-stabilized preparation | |
KR0177493B1 (en) | Process for the preparation of a tablet containing a heat light and moisture sensitive active ingredient having monoclinic crystal structure | |
JP3586471B2 (en) | Torasemide-containing pharmaceutical composition | |
JP3713722B2 (en) | Guayphenesin combination formulation | |
JPH08325145A (en) | Stable isopropylantipyrine-containing preparation | |
JP4999297B2 (en) | High content terbinafine hydrochloride small tablets | |
JPWO2014013928A1 (en) | Stabilized solid preparation for internal use | |
AU756338B2 (en) | Stabile compositions comprising levosimendan and alginic acid | |
JP2021098671A (en) | Pharmaceutical composition containing levetiracetam | |
JP2000086503A (en) | Tablet medicine composition | |
ES2219602T3 (en) | PHARMACEUTICAL COMPOSITION OF CONTROLLED RELEASE CONTAINING BUPROPION HCL AS ACTIVE PRINCIPLE. | |
JPS6051107A (en) | Constant speed release oral solid dosage with high water solubility medicinal compound | |
WO2021117697A1 (en) | Solid pharmaceutical preparation | |
JP2000169367A (en) | Solid pharmaceutical preparation for internal use containing mequitazine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050222 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20050802 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20050815 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080902 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090902 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090902 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090902 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100902 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100902 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110902 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110902 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120902 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120902 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120902 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130902 Year of fee payment: 8 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |